Suppr超能文献

亚洲 II-III 期淋巴结阳性乳腺癌女性的淋巴结病理完全缓解的预测因素。

Predictors of Nodal Pathological Complete Response in Asian Women with Stage II-III Node-Positive Breast Cancer.

机构信息

Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Breast Center, University Hospital of Basel, Basel, Switzerland.

出版信息

Oncology. 2021;99(6):359-364. doi: 10.1159/000513454. Epub 2021 Mar 18.

Abstract

BACKGROUND

Neoadjuvant chemotherapy (NAC) is increasingly used to treat node-positive (N+) breast cancer. Predictors of nodal pathological complete response (pCR) in Asian women are poorly described and there is variety in the management of the axilla after NAC. We evaluated predictors of nodal pCR and axillary management in a cohort of Asian N+ patients.

METHODS

Consecutive biopsy-proven N+ breast cancer patients treated with NAC were identified from the Shanghai Ruijin Hospital in China. Axillary lymph node dissection was performed on all patients, irrespective of the nodal response to NAC.

RESULTS

A total of 323 patients were included. Nodal pCR was achieved in 105 patients (33%), 15% of HR+/HER2- tumors, 38% of HR+/HER2+ tumors, 49% of HR-/HER2+ tumors, and 42% of HR-/HER2-tumors (p < 0.001). Factors associated with nodal pCR were (1) receptor status (HR+/HER2- [referent]: OR 3.42, 95% CI 1.43-8.16, p = 0.006 for HR+/HER2+; OR 4.19, 95% CI 1.85-9.50, p = 0.001 for HR-/HER2+; and OR 2.94, 95% CI 1.11-7.74, p = 0.029 for HR-/HER2-), (2) breast pCR (no pCR [referent]: OR 15.22, 95% CI 6.29-36.79, p < 0.001), and (3) absence of lymphovascular invasion (LVI [referent]: OR 9.04, 95% CI 2.09-39.18, p = 0.003).

CONCLUSION

This study confirmed expected predictors of nodal pCR in Asian women and the benefit of NAC in downstaging the axilla independently of ethnicity.

摘要

背景

新辅助化疗(NAC)越来越多地用于治疗淋巴结阳性(N+)乳腺癌。亚洲女性中预测淋巴结病理完全缓解(pCR)的因素描述不佳,且 NAC 后腋窝的处理方式也各不相同。我们评估了亚洲 N+患者队列中预测淋巴结 pCR 和腋窝处理的因素。

方法

从中国上海瑞金医院确定了接受 NAC 治疗的活检证实的连续 N+乳腺癌患者。所有患者均行腋窝淋巴结清扫术,无论 NAC 对淋巴结的反应如何。

结果

共纳入 323 例患者。105 例(33%)患者达到淋巴结 pCR,其中 HR+/HER2-肿瘤为 15%,HR+/HER2+肿瘤为 38%,HR-/HER2+肿瘤为 49%,HR-/HER2-肿瘤为 42%(p<0.001)。与淋巴结 pCR 相关的因素包括(1)受体状态(HR+/HER2-[参照]:OR 3.42,95%CI 1.43-8.16,p=0.006 用于 HR+/HER2+;OR 4.19,95%CI 1.85-9.50,p=0.001 用于 HR-/HER2+;和 OR 2.94,95%CI 1.11-7.74,p=0.029 用于 HR-/HER2-);(2)乳房 pCR(无 pCR[参照]:OR 15.22,95%CI 6.29-36.79,p<0.001);和(3)无脉管浸润(LVI[参照]:OR 9.04,95%CI 2.09-39.18,p=0.003)。

结论

本研究证实了亚洲女性中预期的淋巴结 pCR 预测因素,以及 NAC 降低淋巴结和腋窝分期的作用与种族无关。

相似文献

本文引用的文献

7
HER2-Low Breast Cancer: Pathological and Clinical Landscape.人表皮生长因子受体2低表达乳腺癌:病理及临床概况
J Clin Oncol. 2020 Jun 10;38(17):1951-1962. doi: 10.1200/JCO.19.02488. Epub 2020 Apr 24.
9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验